Dashboard
Manage Tickers

PRMEPrime Medicine, Inc.

Nasdaq primemedicine.com


$ 7.08 $ 0.04 (0.57 %)    

Friday, 17-May-2024 15:59:30 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 451.63 $ -0.22 (-0.05 %)
DIA $ 399.76 $ 0.74 (0.19 %)
SPY $ 529.24 $ 0.76 (0.14 %)
TLT $ 91.40 $ -0.62 (-0.67 %)
GLD $ 223.63 $ 3.63 (1.65 %)
$ 7.08
$ 6.96
$ 0.00 x 0
$ 0.00 x 0
$ 6.93 - $ 7.18
$ 4.11 - $ 17.20
610,441
na
739.62M
$ 1.14
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-10-2024 03-31-2024 10-Q
2 03-01-2024 12-31-2023 10-K
3 11-03-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-09-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

citigroup-upgrades-prime-medicine-to-buy-announces-10-price-target
Citigroup Upgrades Prime Medicine to Buy, ...
05/16/2024 14:56:57

Citigroup analyst Samantha Semenkow upgrades Prime Medicine (NASDAQ:PRME) from Neutral to Buy and announces $10 price target.

jp-morgan-maintains-overweight-on-prime-medicine-lowers-price-target-to-15
JP Morgan Maintains Overweight on Prime Me...
05/13/2024 14:45:20

JP Morgan analyst Eric Joseph maintains Prime Medicine (NASDAQ:PRME) with a Overweight and lowers the price target from $16 ...

prime-medicine-q1-2024-gaap-eps-044-beats-047-estimate
Prime Medicine Q1 2024 GAAP EPS $(0.44) Be...
05/10/2024 12:02:10

Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.47...

prime-medicine-presents-preclinical-data-demonstrating-ability-of-pm359-to-efficiently-reproducibly-and-durably-correct-causative-mutation-of-chronic-granulomatous-disease
Prime Medicine Presents Preclinical Data D...
05/08/2024 12:12:19

Findings demonstrate ability of PM359 to correct disease-causing mutation in CGD patient blood stem cells, leading to restored ...

jefferies-assumes-prime-medicine-at-buy-lowers-price-target-of-15
Jefferies Assumes Prime Medicine at Buy, L...
05/07/2024 14:56:34

Jefferies analyst Maury Raycroft assumes Prime Medicine (NASDAQ:PRME) with a Buy rating and lowers Price Target of $15.

why-aspen-aerogels-shares-are-trading-higher-by-26-here-are-20-stocks-moving-premarket
Why Aspen Aerogels Shares Are Trading High...
05/02/2024 09:43:31

Core News & Articles
Why Clever Leaves Holdings Shares Are Trad...
04/29/2024 17:04:01

tesla-deciphera-pharmaceuticals-heartland-financial-and-other-big-stocks-moving-higher-on-monday
Tesla, Deciphera Pharmaceuticals, Heartlan...
04/29/2024 14:47:40

prime-medicine-reports-fda-clearance-of-investigational-new-drug-application-for-pm359-for-treatment-of-chronic-granulomatous-disease
Prime Medicine Reports FDA Clearance Of In...
04/29/2024 11:05:00

Prime Medicine expects to report initial clinical data from the study in 2025.

prime-medicine-announces-fda-clearance-of-investigational-new-drug-ind-application-for-pm359-for-the-treatment-of-chronic-granulomatous-disease-cgd
Prime Medicine Announces FDA Clearance of ...
04/29/2024 11:01:04

Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated, one-time cur...

12-health-care-stocks-moving-in-fridays-after-market-session
12 Health Care Stocks Moving In Friday's A...
04/26/2024 20:31:15

wedbush-reiterates-outperform-on-prime-medicine-maintains-12-price-target
Wedbush Reiterates Outperform on Prime Med...
04/23/2024 17:14:48

Wedbush analyst David Nierengarten reiterates Prime Medicine (NASDAQ:PRME) with a Outperform and maintains $12 price target.

prime-medicine-to-present-preclinical-data-demonstrating-broad-potential-of-prime-editing-technology-at-upcoming-scientific-meetings
Prime Medicine To Present Preclinical Data...
04/23/2024 12:18:43

-- Presentations include new preclinical data for PM359, further demonstrating ability of Prime Editors to efficiently, reprodu...

chardan-capital-initiates-coverage-on-prime-medicine-with-buy-rating-announces-price-target-of-17
Chardan Capital Initiates Coverage On Prim...
04/22/2024 11:49:55

Chardan Capital analyst Geulah Livshits initiates coverage on Prime Medicine (NASDAQ:PRME) with a Buy rating and announces P...

td-cowen-initiates-coverage-on-prime-medicine-with-buy-rating
TD Cowen Initiates Coverage On Prime Medic...
04/08/2024 21:19:06

TD Cowen analyst Joseph Thome initiates coverage on Prime Medicine (NASDAQ:PRME) with a Buy rating.

prime-medicine-shares-are-trading-higher-after-wedbush-initiated-coverage-on-the-stock-with-an-outperform-rating-and-12-price-target
Prime Medicine shares are trading higher a...
04/03/2024 11:49:17

wedbush-initiates-coverage-on-prime-medicine-with-outperform-rating-announces-price-target-of-12
Wedbush Initiates Coverage On Prime Medici...
04/03/2024 09:29:47

Wedbush analyst David Nierengarten initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces...

wedbush-initiates-coverage-on-prime-medicine-with-outperform-rating-announces-price-target-of-12
Wedbush Initiates Coverage On Prime Medici...
04/02/2024 20:24:49

Wedbush analyst David Nierengarten initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces...

guggenheim-maintains-buy-on-prime-medicine-lowers-price-target-to-20
Guggenheim Maintains Buy on Prime Medicine...
03/05/2024 17:04:04

Guggenheim analyst Debjit Chattopadhyay maintains Prime Medicine (NASDAQ:PRME) with a Buy and lowers the price target from $...

recap-prime-medicine-q4-earnings
Recap: Prime Medicine Q4 Earnings
03/01/2024 13:15:06

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION